Edaravone for amyotrophic lateral sclerosis; Neonatal mortality in US planned home births by UpToDate

Edaravone for amyotrophic lateral sclerosis; Neonatal mortality in US planned home births

UpToDate® is the premier evidence-based clinical decision support resource, trusted worldwide by healthcare practitioners to help them make the right decisions at the point of care. It is proven to change the way clinicians practice medicine, and is the only resource of its kind associated with improved outcomes.

Support for UpToDate Talk is provided by UpToDate, Wolters Kluwer. UpToDate is entirely funded by the subscriptions of its users and does not accept advertising or funding unrelated to subscriptions. The opinions in such podcasts are entirely those of the discussants, and these discussants are authors and editors for UpToDate. View UpToDate’s conflict of interest policy:  http://www.uptodate.com/home/conflict-interest-policy.

Please note that we are no longer producing new clinical podcasts.

Science

UpToDate® is the premier evidence-based clinical decision support resource, trusted worldwide by healthcare practitioners to help them make the right decisions at the point of care. It is proven to change the way clinicians practice medicine, and is the only resource of its kind associated with improved outcomes. Support for UpToDate Talk is provided by UpToDate, Wolters Kluwer. UpToDate is entirely funded by the subscriptions of its users and does not accept advertising or funding unrelated to subscriptions. The opinions in such podcasts are entirely those of the discussants, and these discussants are authors and editors for UpToDate. View UpToDate’s conflict of interest policy: http://www.uptodate.com/home/conflict-interest-policy. Please note that we are no longer producing new clinical podcasts.

Share Edaravone for amyotrophic lateral sclerosis; Neonatal mortality in US planned home births

Sign up to save your podcasts

Edaravone for amyotrophic lateral sclerosis; Neonatal mortality in US planned home births

Edaravone for amyotrophic lateral sclerosis; Neonatal mortality in US planned home births